Investigation of Genetic Polymorphisms of Cytochrome P450 2C19 in Iranian Patients with Drug-Eluting Stents

Mahdiye  Abiyarghamsari; Farshad  Hosseini Shirazi; Mohammad  Sistanizad

doi:10.18502/jpc.v13i3.20320

Mahdiye Abiyarghamsari Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farshad Hosseini Shirazi Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mohammad Sistanizad Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

DOI: https://doi.org/10.18502/jpc.v13i3.20320

Keywords: Genetic; Polymorphism; CYP; Cytochrome; P450

Abstract

Background: Cytochrome P450 2C19 (CYP2C19) exhibits polymorphism, with about 21 known allelic variants. Notably, the ^*17 allele is associated with increased enzymatic activity, culminating in enhanced CYP2C19 activity and the ultra-rapid metabolizer (UM) phenotype. This genetic variation has a profound impact on an individual's response to a wide range of medications. The primary objective of this study was to ascertain the prevalence of the CYP2C19^*17 allele among Iranian patients who have received drug-eluting stents.

Methods: This study was conducted to examine the genetic polymorphism of the CYP2C19 enzyme in 100 patients with drug-eluting stents (DESs) at Imam Hossein Hospital, Tehran, Iran. All participants were selected based on pre-defined inclusion criteria. Blood samples were obtained for DNA extraction, and CYP2C19 genotypes were subsequently analyzed through polymerase chain reaction (PCR) and gel electrophoresis.

Results: The ^*17 polymorphism was detected in 11% of the cohort. Of this group, 11 individuals were heterozygous carriers of the CYP2C19^*17 allele, whereas the homozygous ^*17/^*17 genotype was not observed in any participant.

Conclusion: Our findings demonstrate a low prevalence of the CYP2C19^*17 allele and an absence of the homozygous ^*17/^*17 genotype in the Iranian population. Despite its lower prevalence compared to other populations, the clinical implications of this allele are still considered highly significant.